ICYMI: Research Roundup from CROI 2024

At the recent 2024 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with colleagues from NIH and CDC as well as community members about the latest research on HIV and other infectious diseases being presented at the annual event. Here’s a roundup of key topics covered in those video conversations and related blog posts so you can catch up on any that you may have missed and share them with your friends and colleagues.

To learn about the latest research on:

• HIV testing, check out our conversation with CDC’s Dr. Robin Neblett Fanfair, who discussed results from the Together TakeMeHome HIV self-test kit distribution project showing that the tests are reaching priority populations.
• HIV PrEP, view our conversations with CDC’s Dr. Jonathan Mermin, who discussed studies on long-acting PrEP; CDC’s Dr. Neblett Fanfair, who highlighted analysis of PrEP use among people who inject drugs; Yale University’s Dr. LaRon Nelson, who remarked on research highlights as well as a new study he and colleagues are launching that aims to reduce HIV rates among Black men who have sex with men in the southern United States; and Emory University’s Patrick Sullivan, who is also a member of the Presidential Advisory Council on HIV/AIDS (PACHA), discussing his team’s analysis that found that over the past decade, U.S. states with high PrEP coverage among those who need it experienced steeper declines in new HIV diagnosis rates than states with low PrEP coverage.
• HIV treatment, check out our conversation with NIH’s Dr. Carl Dieffenbach, who highlighted several studies on current long-acting treatment options and possible future options that may be even longer-lasting.
• Liver and cardiovascular complications of HIV, watch our conversation with Dr. Dieffenbach.
• HIV and aging, see our conversation with Jeff Taylor, Director of the HIV and Aging Research Project and a member of PACHA, who highlighted findings that continue to come from the REPRIEVE trial, a global study that demonstrated that a statin, a cholesterol-lowering medication, may offset the high risk of cardiovascular disease in people with HIV by more than a third.
• HIV vaccine research, view this conversation with NIH’s Dr. Dieffenbach.
• ART-free remission, check out this discussion with Johns Hopkins University’s Dr. Deborah Persaud about a study she’s involved in examining whether very early initiation of antiretroviral therapy (ART) may limit the establishment of HIV reservoirs in newborns, potentially enabling ART-free remission.
• Doxy-PEP: The use of doxycycline for STI post-exposure prophylaxis, including insights from Doxy-PEP use in real-world settings, view our conversations with NIH’s Dr. Dieffenbach and CDC’s Dr. Mermin.
• Expanding access to syphilis testing, take a look at this post about Dr. Kimberly Stanford’s work in a Chicago hospital emergency department that integrated routine, non-targeted, opt-out syphilis testing and substantially increased the proportion of pregnant persons who were screened for syphilis and found a 750% increase in the number of syphilis cases diagnosed among them, providing an opportunity to intervene and prevent congenital syphilis.
• Community-informed research, don’t miss our conversations with The Well Project’s Bridgette Picou and NMAC’s Damián Cabrera, our conversation with Yale’s Dr. Nelson, and our conversation with NIH’s Dr. Dieffenbach, who highlighted the importance of partnership between the HIV community and scientists in all aspects of HIV research.

We also shared our first conversation with Dr. Jeanne Marrazzo, the new Director of NIH’s National Institute of Allergy and Infectious Diseases. She previewed CROI and talked about the importance of mentoring early career investigators.

You can also find these videos to view and share on this HIV.gov YouTube playlistExit Disclaimer, as well as on HIV.gov’s Facebook pageExit Disclaimer, X/TwitterExit Disclaimer, and on the LinkedIn page for the HHS Office of Infectious Disease and HIV/AIDS PolicyExit Disclaimer.